Seaport Therapeutics, Inc.(SPTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
SPTX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Seaport Therapeutics, Inc. (SPTX), a Healthcare sector company. SPTX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Seaport Therapeutics, Inc. reports net income of $-25.4M, free cash flow of $-20.2M. SPTX trades on the Nasdaq exchange and files with the SEC under CIK 2042347. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SPTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Seaport Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-25.4M
Free Cash Flow
Q1 2026
$-20.2M
AI Insight: SPTX Financial Trends
Seaport Therapeutics is pre-revenue with significant quarterly cash burn and negative equity, indicating early-stage biotech development phase.
• Operating loss of $28M in Q1 2026; operating cash burn of $20M reflects R&D-heavy, pre-commercialization stage.
⚠ Negative equity of $116M signals accumulated losses exceed paid-in capital; runway and financing risk critical.
AI Insight: SPTX Ratio Trends
Single-quarter snapshot shows severe losses with no historical context to assess trend direction.
• ROA of -44.6% in Q1 2026 reflects substantial net losses; insufficient data for trend analysis.
⚠ Operating margin, NPM, ROE, ROIC, and leverage metrics all missing — unable to assess profitability or capital efficiency.
⚠ Only one quarter of data available; multi-quarter history required to distinguish seasonality from structural decline.
Get alerted when SPTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Seaport Therapeutics, Inc. including:
More Healthcare Companies
View all Healthcare →Put SPTX on your watchlist
Track score changes the day Seaport Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SPTX a good stock to buy?
13F Pro's AI-powered analysis of Seaport Therapeutics, Inc. (SPTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SPTX are available on the SPTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own SPTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SPTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Seaport Therapeutics, Inc.'s investment landscape.